Breakthrough in Treatment for Macular Degeneration Blindness by Mesogen Inc.

Mesogen Inc., based in The Woodlands, Texas, announced a significant development in the treatment of Macular Degeneration Blindness. The company has engineered a transplantable Retinal Pigmented Epithelium (RPE) patch derived from autologous bone marrow stem cells. This new method offers a significant advancement as it presents no risk of teratoma tumors and does not require immunosuppression.

With twenty million Americans suffering from Macular Degeneration, and two million of them blind due to this condition, the need for effective treatment is urgent. Historical methods using embryonic stem cells posed risks and complications, which Mesogen's new technique, utilizing patient-specific stem cells and an electrospun PLGA patch, seeks to eliminate.

Mesogen’s innovation could potentially be the first marketable cure to not only treat but significantly improve vision for patients with Macular Degeneration. The company currently holds two patents for their novel methods, with another pending, aiming to achieve market readiness by 2025. They are now actively seeking strategic investors to support this initiative.